Araújo A, et al. An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer Rev Port Pneumol 2008; 14(6):803–827

Bartminski, Wojciech

doi:10.1016/S2173-5115(09)70132-0

array:24 ["pii" => "S2173511509701320" "issn" => "21735115" "doi" => "10.1016/S2173-5115(09)70132-0" "estado" => "S300" "fechaPublicacion" => "2009-05-01" "aid" => "70132" "copyright" => "Sociedade Portuguesa de Pneumologia" "copyrightAnyo" => "2009" "documento" => "simple-article" "crossmark" => 0 "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "cor" "cita" => "Rev Port Pneumol. 2009;15:555-9" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 3338 "formatos" => array:3 [ "EPUB" => 188 "HTML" => 1786 "PDF" => 1364 ] ] "itemSiguiente" => array:19 [ "pii" => "S2173511509701332" "issn" => "21735115" "doi" => "10.1016/S2173-5115(09)70133-2" "estado" => "S300" "fechaPublicacion" => "2009-05-01" "aid" => "70133" "copyright" => "Sociedade Portuguesa de Pneumologia" "documento" => "simple-article" "crossmark" => 0 "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "cor" "cita" => "Rev Port Pneumol. 2009;15:560-6" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 3360 "formatos" => array:3 [ "EPUB" => 180 "HTML" => 1807 "PDF" => 1373 ] ] "en" => array:8 [ "idiomaDefecto" => true "titulo" => "Araújo A, et al. An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer Rev Port Pneumol 2008; 14(6):803–827" "tienePdf" => "en" "tieneTextoCompleto" => 0 "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "560" "paginaFinal" => "566" ] ] "titulosAlternativos" => array:1 [ "pt" => array:1 [ "titulo" => "Araújo A, et al. Avaliação económica do erlotinib, docetaxel, pemetrexedo e tratamento de suporte no tratamento de segunda ou terceira linhas de doentes com cancro do pulmão de não pequenas células Rev Port Pneumol 2008; 14(6):803–827" ] ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "António Araújo" "autores" => array:1 [ 0 => array:2 [ "nombre" => "António" "apellidos" => "Araújo" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173511509701332?idApp=UINPBA00004E" "url" => "/21735115/0000001500000003/v1_201305151509/S2173511509701332/v1_201305151509/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S2173511509701319" "issn" => "21735115" "doi" => "10.1016/S2173-5115(09)70131-9" "estado" => "S300" "fechaPublicacion" => "2009-05-01" "aid" => "70131" "copyright" => "Sociedade Portuguesa de Pneumologia" "documento" => "simple-article" "crossmark" => 0 "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "cor" "cita" => "Rev Port Pneumol. 2009;15:553-4" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2268 "formatos" => array:3 [ "EPUB" => 205 "HTML" => 1127 "PDF" => 936 ] ] "pt" => array:7 [ "idiomaDefecto" => true "titulo" => "Carta ao Editor" "tienePdf" => "pt" "tieneTextoCompleto" => 0 "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "553" "paginaFinal" => "554" ] ] "contienePdf" => array:1 [ "pt" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Maria João Marques Gomes" "autores" => array:1 [ 0 => array:2 [ "nombre" => "Maria João" "apellidos" => "Marques Gomes" ] ] ] ] ] "idiomaDefecto" => "pt" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173511509701319?idApp=UINPBA00004E" "url" => "/21735115/0000001500000003/v1_201305151509/S2173511509701319/v1_201305151509/pt/main.assets" ] "en" => array:10 [ "idiomaDefecto" => true "titulo" => "Araújo A, et al. An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer Rev Port Pneumol 2008; 14(6):803–827" "tieneTextoCompleto" => 0 "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "555" "paginaFinal" => "559" ] ] "autores" => array:1 [ 0 => array:3 [ "autoresLista" => "Wojciech Bartminski" "autores" => array:1 [ 0 => array:3 [ "preGrado" => "MD MSc" "nombre" => "Wojciech" "apellidos" => "Bartminski" ] ] "afiliaciones" => array:1 [ 0 => array:1 [ "entidad" => "European Outcomes Research, Health Outcomes Scientist, Oncology & Neuroscience, EMS AREA" ] ] ] ] "titulosAlternativos" => array:1 [ "pt" => array:1 [ "titulo" => "Araújo A, et al. Avaliação económica do erlotinib, docetaxel, pemetrexedo e tratamento de suporte no tratamento de segunda ou terceira linhas de doentes com cancro do pulmão de não pequenas células Rev Port Pneumol 2008; 14(6):803–827" ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "bibliografia" => array:2 [ "titulo" => "Bibliography/Bibliografia" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:15 [ 0 => array:3 [ "identificador" => "bib1" "etiqueta" => "1." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:1 [ 0 => "A. Araujo" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:7 [ "tituloSerie" => "Rev Port Pneumol" "fecha" => "2008" "volumen" => "14" "numero" => "6" "paginaInicial" => "803" "paginaFinal" => "827" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19023496" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib2" "etiqueta" => "2." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Peterson P, et al. Is pemetrexed more effective in patients with non-squamous histology? A retrospective analysis of a phase III trial of pemetrexed vs. docetaxel in previously treated patients with advanced nonsmall cell lung cancer (NSCLC). Abstract P#6521, The European Cancer Conference 2007 (ECCO 14). Eur J Cancer 2007;5 (Suppl 4):363." ] ] ] 2 => array:3 [ "identificador" => "bib3" "etiqueta" => "3." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Drummond M, Sculpher M, Torrance G, et al. Methods for the economic evaluation of health care programmes. Oxford Medical Publications; Third edition, 200; 48-51, 121–124, 190–196." ] ] ] 3 => array:3 [ "identificador" => "bib4" "etiqueta" => "4." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:1 [ 0 => "F. Song" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/bmj.326.7387.472" "Revista" => array:6 [ "tituloSerie" => "BMJ" "fecha" => "2003" "volumen" => "326" "numero" => "7387" "paginaInicial" => "472" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12609941" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib5" "etiqueta" => "5." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Indirect comparisons of competing interventions" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A.M. Glenny" 1 => "D.G. Altman" 2 => "F. Song" 3 => "C. Sakarovitch" 4 => "J.J. Deeks" 5 => "R. D’Amico" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "Health Technol Assess" "fecha" => "2005" "volumen" => "9" "numero" => "26" ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib6" "etiqueta" => "6." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "da Silva AE, et al. Orientações metodológicas para estudos de avaliação económica de medicamentos. INFARMED 1998 <a class="elsevierStyleInterRef" href="http://www.infarmed.pt/portal/page/portal/infarmed/medicamentos_uso_humano/ava%20liacao_economica_e_comparticipacao/medicamen%20tos_uso_ambulatorio/avaliacao_de_comparticipacao/orien_metodologicas_eaem.pdf">http://www.infarmed.pt/portal/page/portal/infarmed/medicamentos_uso_humano/avaliacao_economica_e_comparticipacao/medicamentos_uso_ambulatorio/avaliacao_de_comparticipacao/orien_metodologicas_eaem.pdf</a>." ] ] ] 6 => array:3 [ "identificador" => "bib7" "etiqueta" => "7." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "European Product Assessment Report (EPAR) and Product Information: Alimta. CHMP 2008 <a class="elsevierStyleInterRef" href="http://www.emea.europa.eu/humandocs/Humans/EPAR/al%20imta/alimta.htm">http://www.emea.europa.eu/humandocs/Humans/EPAR/al imta/alimta.htm</a>." ] ] ] 7 => array:3 [ "identificador" => "bib8" "etiqueta" => "8." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "European Product Assessment Report (EPAR) and Product Information: Tarceva. CHMP 2008 <a class="elsevierStyleInterRef" href="http://www.emea.europa.eu/humandocs/Humans/EPAR/tarceva/tarceva.htm">http://www.emea.europa.eu/humandocs/Humans/EPAR/tarceva/tarceva.htm</a>." ] ] ] 8 => array:3 [ "identificador" => "bib9" "etiqueta" => "9." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "European Product Assessment Report (EPAR) and Product Information: Taxotere. CHMP 2008 <a class="elsevierStyleInterRef" href="http://www.emea.europa.eu/humandocs/Humans/EPAR/tax%20otere/taxotere.htm">http://www.emea.europa.eu/humandocs/Humans/EPAR/tax otere/taxotere.htm</a>." ] ] ] 9 => array:3 [ "identificador" => "bib10" "etiqueta" => "10." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "N. Hanna" 1 => "F.A. Shepherd" 2 => "F.V. Fossela" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/JCO.2004.08.163" "Revista" => array:6 [ "tituloSerie" => "J Clin Oncol" "fecha" => "2004" "volumen" => "22" "paginaInicial" => "1589" "paginaFinal" => "1597" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15117980" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib11" "etiqueta" => "11." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "NICE Technology Appraisal TA162. November 2008. Erlotinib for the treatment of non-small cell lung cancer. Pages 11-12 <a class="elsevierStyleInterRef" href="http://www.nice.org.uk/Guidance/TA162">http://www.nice.org.uk/Guidance/TA162</a>." ] ] ] 11 => array:3 [ "identificador" => "bib12" "etiqueta" => "12." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Erlotinib in previously treated non-small cell lung cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "F.A. Shepherd" 1 => "J. Pereira" 2 => "T. Ciuleanu" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa050753" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2005" "volumen" => "353" "paginaInicial" => "123" "paginaFinal" => "132" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16014882" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib13" "etiqueta" => "13." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:1 [ 0 => "F.A. Shepherd" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/jco.2000.18.10.2095" "Revista" => array:7 [ "tituloSerie" => "Journal of Clinical Oncology" "fecha" => "2000" "volumen" => "18" "numero" => "10" "paginaInicial" => "2095" "paginaFinal" => "2103" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10811675" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib14" "etiqueta" => "14." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Methods for the economic evaluation of health care programmes" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "M. Drummond" 1 => "M. Sculpher" 2 => "G. Torrance" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:2 [ "fecha" => "2005" "editorial" => "Oxford Medical Publications; Third edition" ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib15" "etiqueta" => "15." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Letter to the Editor: A comparison of the estimated costs of erlotinib, docetaxel and pemetrexed for the second-line treatment of non-small cell lung cancer from the German healthcare perspective" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "J. Arellano" 1 => "C. Leteneux" 2 => "W. Kotowa" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3111/13696990802113147" "Revista" => array:7 [ "tituloSerie" => "Journal of Medical Economics" "fecha" => "2008" "volumen" => "11" "numero" => "2" "paginaInicial" => "363" "paginaFinal" => "370" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19450092" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] "lecturaRecomendada" => array:1 [ 0 => array:3 [ "vista" => "all" "titulo" => "Further readings/Leituras adicionais" "seccion" => array:1 [ 0 => array:1 [ "bibliografiaReferencia" => array:2 [ 0 => array:3 [ "identificador" => "bib16" "etiqueta" => "NICE, 2007." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "NICE Technology Appraisal TA124. August 2007. Pemetrexed for the treatment of non-small-cell lung cancer. <a class="elsevierStyleInterRef" href="http://www.nice.org.uk/Guidance/TA124">http://www.nice.org.uk/Guidance/TA124</a>" ] ] ] 1 => array:3 [ "identificador" => "bib17" "etiqueta" => "American, 2006." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "American Pharmaceutical Group criticizes NICE approach vs. Alimta: UK parliamentary Select Committee on Health documents: <a class="elsevierStyleInterRef" href="http://www.publications.parliament.uk/pa/cm200607/cmselect/cmhealth/503/503we06.htm">http://www.publications.parliament.uk/pa/cm200607/cmselect/cmhealth/503/503we06.htm</a>." ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/21735115/0000001500000003/v1_201305151509/S2173511509701320/v1_201305151509/en/main.assets" "Apartado" => array:4 [ "identificador" => "9640" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Letter to the Editor/Carta ao Editor" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/21735115/0000001500000003/v1_201305151509/S2173511509701320/v1_201305151509/en/main.pdf?idApp=UINPBA00004E&text.app=https://journalpulmonology.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173511509701320?idApp=UINPBA00004E"]

Article information

Bibliography

Download PDF

Statistics

Full text is only aviable in PDF

Indexed in:

Follow us:

Indexed in:

Follow us:

Subscribe to our newsletter